Last reviewed · How we verify
Disease-modifying antirheumatic drug
Disease-modifying antirheumatic drugs (DMARDs) suppress the underlying immune-mediated inflammatory processes that drive rheumatoid arthritis and other autoimmune conditions.
Disease-modifying antirheumatic drugs (DMARDs) suppress the underlying immune-mediated inflammatory processes that drive rheumatoid arthritis and other autoimmune conditions. Used for Rheumatoid arthritis, Other autoimmune inflammatory conditions (specific indication dependent on individual agent).
At a glance
| Generic name | Disease-modifying antirheumatic drug |
|---|---|
| Also known as | DMARD, MTX |
| Sponsor | Pfizer |
| Drug class | Disease-modifying antirheumatic drug (DMARD) |
| Modality | Small molecule |
| Therapeutic area | Immunology / Rheumatology |
| Phase | Phase 3 |
Mechanism of action
DMARDs work through various mechanisms including immunosuppression, cytokine inhibition, and modulation of T-cell or B-cell function to reduce joint inflammation and slow radiographic progression. Unlike NSAIDs and corticosteroids that primarily manage symptoms, DMARDs target the disease pathology itself and can induce remission or low disease activity. Pfizer's DMARD pipeline includes both conventional synthetic DMARDs and biologic agents targeting specific immune pathways.
Approved indications
- Rheumatoid arthritis
- Other autoimmune inflammatory conditions (specific indication dependent on individual agent)
Common side effects
- Infection (including serious infections)
- Hepatotoxicity
- Bone marrow suppression
- Gastrointestinal disturbances
- Rash
Key clinical trials
- The SetPoint System Safety & Performance Post-Approval Study
- IL6-receptor Inhibitor Iwith Belumosudil for the Treatment of Belumosudil-refractory cGVHD (PHASE1)
- A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines (PHASE3)
- Coronavirus Anxiety in Patients Using Biologic vs Conventional DMARDs
- Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug (PHASE3)
- A Study of Clinical and Immune Responses to Sequential Biologic Therapies in Psoriatic Arthritis
- Phase IIb Clinical Study to Assess the Efficacy and Safety of GenSci120 Injection in Patients With Moderately to Severely Active RA Who Have an Inadequate Response to at Least One DMARD (PHASE2)
- Modifying PEST for Psoriatic Arthritis Screening (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Disease-modifying antirheumatic drug CI brief — competitive landscape report
- Disease-modifying antirheumatic drug updates RSS · CI watch RSS
- Pfizer portfolio CI